CompletedObservationalLast updated Nov 30, 2012

BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )

An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety of BONVIVA(Ibandronate) Administered in Korean Patients According to the Prescribing Information

Overview

ClinicalTrials.gov ID: NCT01381393
Lead Sponsor: GlaxoSmithKlineINDUSTRY
Brief Summary: This is an open label, multi-centre, non-interventional post-marketing surveillance.
Study Type: Observational

Status

Overall Status: Completed
Start Date: Jun 2007
Primary Completion Date: Mar 2012Actual
Completion Date: Mar 2012Actual

Study Record Dates

First Submitted: Jun 23, 2011
First Submitted that Met QC Criteria: Jun 23, 2011
First Posted: Jun 27, 2011Estimated
Last Update Submitted that Met QC Criteria: Nov 28, 2012
Last Update Posted: Nov 30, 2012Estimated
Last Verified: Nov 2012

NCT01376102Completed

BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)

NCT02271204Completed

Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis

NCT01290094Completed

A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis

NCT00493532No longer available

A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

NCT00048061Completed

MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

NCT02604836Completed

A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia